Background In patients (pts) with early RA receiving MTX, remission improves long-term functional and structural outcomes. However, dissociation between clinical and structural outcomes has been reported with biologic treatment of early RA in pts with poor prognostic factors.
Objectives To explore changes in structural and functional outcomes at Month(M)12 according to disease activity at M3 in the AGREE trial.
Methods In AGREE, pts with early RA and poor prognostic factors were randomized to ABA+MTX or MTX alone for 12 months.1 This was a post hoc, as-observed analysis of mean (95% CI) change from baseline (BL) to M12 in Genant-modified Sharp TS and HAQ-DI score according to DAS28, SDAI and CDAI status at M3, for pts with efficacy data available at BL, M6 and M12.
Results Mean BL scores for disease activity, structural and functional status were similar between original treatment groups.1 Change from BL to M12 in X-ray TS and HAQ-DI scores according to M3 disease activity status (low [LDA]; moderate [MDA]; high [HDA]) are shown.
Conclusions This post hoc analysis indicated numerical trends that remission or LDA at M3 may be associated with less X-ray progression and greater functional improvements from BL to M12 than moderate/high disease at M3; somewhat less progression of X-ray score with ABA+MTX vs MTX alone was also observed in pts with moderate/high disease at M3, suggesting a protective effect of ABA on joint damage even in these pts; ABA+MTX conferred greater reductions in HAQ-DI score vs MTX alone, regardless of disease activity.
Westhovens R, et al. Ann Rheum Dis 2009;68:1870–7
Disclosure of Interest J. Smolen Grant/research support from: Abbott, Bristol-Myers Squibb, Hoffmann-La Roche, Schering-Plough, UCB, Pfizer, Consultant for: Abbott, Amgen, AstraZeneca, Bristol-Myers Squibb, Centocor, Eli-Lilly, Merck, Novo Nordisk, Roche, sanofi-aventis, UCB, Y. Yazici Grant/research support from: Centocor, Bristol-Myers Squibb, Genentech, Consultant for: Bristol-Myers Squibb, Celgene, Genentech, Horizon, UCB, Roche, Pfizer, Speakers bureau: Bristol-Myers Squibb, J. Wollenhaupt Consultant for: Bristol-Myers Squibb, Chugai, Roche, Speakers bureau: Chugai, Roche, P. Durez Speakers bureau: Bristol-Myers Squibb, J. Gomez-Reino Grant/research support from: Roche, Schering-Plough, Wyeth Pharmaceuticals, UCB, Consultant for: Hoffmann-La Roche, Roche, Schering-Plough, UCB, Pfizer, Bristol-Myers Squibb, Speakers bureau: Bristol-Myers Squibb, Roche, UCB, MSD, Pfizer, Abbott, W. Grassi Grant/research support from: Abbott, Bristol-Myers Squibb, Esaote, General Electric, Menarini, Merck Sharp & Dohme, Pfizer, Roche, Schering-Plough, UCB, Consultant for: Abbott, Bristol-Myers Squibb, Esaote, General Electric, Menarini, Merck Sharp & Dohme, Pfizer, Roche, Schering-Plough, UCB, M. Le Bars Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, C. Gaillez Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, C. Poncet Consultant for: Bristol-Myers Squibb, R. Westhovens Grant/research support from: Roche, UCB, Consultant for: Bristol-Myers Squibb, Galapagos, Janssen, Speakers bureau: Bristol-Myers Squibb
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.